Newsroom

News

The bacterium Pseudomonas aeruginosa is among the most common causes of pneumonia and poses a major challenge to hospitals worldwide. The treatment of infections with Pseudomonas aeruginosa is usually challenging because the bacterium forms so-called biofilms, which protect it from drugs. Dr Martin Empting and his team, in collaboration with several groups at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), have now developed an innovative method to disrupt the formation of these biofilms and thus facilitate the treatment of infections with Pseudomonas aeruginosa. The researchers have published their findings in the journal Advanced Science.

19.03.2021

HZI Campus

HIPS

Grafik Myelom-Zellen mit BCMA-Expression

News

Therapeutically modified white blood cells hold great potential in the treatment of multiple myeloma, a malignant cancer of the bone marrow. However, they can lead to serious resistance in treated patients. In close cooperation, medical doctors and scientists from the University Hospital and the Helmholtz Institute for RNA-based Infection Research in Würzburg have now investigated the causes of this previously unexplained phenomenon. In the process, they uncovered a crucial resistance mechanism. The results were just published in the journal Nature Medicine.

11.03.2021

HIRI

News

An international research team of the Technische Universität Braunschweig and the Helmholtz Centre for Infection Research (HZI), led by the Department of Biotechnology of the TU Braunschweig, has reported on the development of special antibodies against SARS-CoV-2 in the journal Nature Communications. These antibodies prevent the viruses from entering host cells and were isolated from an antibody gene library that had already been produced from immune cells of healthy donors before the pandemic. The study shows how, in the future, active substances to previously unknown, emerging viruses can be produced very quickly without patient material.

11.03.2021

HZI Campus

News

The CoVerage tool analyses the lineage dynamics of SARS-CoV-2 strains, i.e. determines how successfully which virus strain spreads. The web resource uses input from the Gisaid genome database. Gisaid is an international initiative that aims to make research data rapidly available to the public. Scientists from all over the world contribute genome sequences of viruses such as H1N1, influenza or SARS-CoV-2 to the database, thus providing a broad overview of mutations and their genetic differences. However, to predict the spread potential of these mutations, a simple count of incidences is not sufficient.

04.03.2021

HZI Campus

News

The NoCovid group’s scientists, including HZI researchers Prof Melanie Brinkmann and Prof Michael Meyer-Hermann, have called for extensive testing, faster contact tracing, and a rapid rollout of vaccinations in Germany, arguing that only then will it be possible to open up the economy again. Any reopening in the immediate future threatens to quickly undo the hard-won successes of recent weeks, the group writes in a new paper. This means testing must become a part of everyday life. “If we want the economy to recover, any reopening has to be backed by an effective testing strategy and must not be permitted to lead to a resurgence of infections,” says Clemens Fuest, ifo President and a member of the group.

02.03.2021

HZI Campus

Elektronenmikroskopische Aufnahme einer T-Zelle

News

As part of the adaptive immune system, T cells are involved in the defence against pathogens. However, if they recognise healthy, self-structures instead of invading pathogens, autoimmune diseases can result. It is still insufficiently understood which factors are responsible for the dysregulation of the T cells. A new EU-funded programme for young researchers, coordinated by Prof. Jochen Hühn at the Helmholtz Centre for Infection Research (HZI) in Braunschweig, aims to study tissue-resident T cells in more detail. Within the framework of the training network, 15 doctoral students will be trained at academic and non-academic institutions in ten European countries.

01.03.2021

HZI Campus

Back to the first page
...
47
48
49
50
...
136

HZI in the media

Hochschule Hannover, die Universitätsmedizin Göttingen, das Helmholtz-Zentrum für Infektionsforschung in Braunschweig sowie die KI-

07.11.2025

Heise online

... , Leiter der Forschungsgruppe Mikrobielle Wirkstoffe am Helmholtz-Zentrum für Infektionsforschung, zu bedenken. Das erste ...

07.11.2025

Leipziger Volkszeitung (LVZ)

Quelle: Pressemitteilung

HZI-Helmholtz Zentrum für Infektionsforschung ...

04.11.2025

LaborPraxis

Forschende des Helmholtz-Zentrums für Infektionsforschung und der Universität Würzburg entwickeln derzeit einen Kaugummi, der Grippeviren

04.11.2025

Arbeitsmedizin-Sozialmedizin-Umweltmedizin

... Vakzinologie und angewandte Mikrobiologie am Helmholtz-Zentrum für Infektionsforschung. Die M2-Membranproteinhemmer verhindern ...

02.11.2025

Augsburger Allgemeine

... etwas dran ist“, erklärt Biologe Marc Stadler vom Helmholtz-Zentrum für Infektionsforschung gegenüber der Barmer-Krankenkasse. „Es ...

30.10.2025

bild der wissenschaft

could be reintroduced at any time. Epidemiologists at the Helmholtz Center for Infection Research (HZI) have now shown that many people do

23.10.2025

MSN.com

... eingeschleppt werden könnte. Epidemiolog:innen des Helmholtz-Zentrums für Infektionsforschung (HZI) haben nun gezeigt, dass ...

23.10.2025

innovations report

this development, a research team at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), in collaboration with the Swiss

22.10.2025

Phys.org

Malaria-Medikamentes ermöglichen könnte. Das HIPS ist ein Standort des Helmholtz-Zentrums für Infektionsforschung in Zusammenarbeit mit ...

22.10.2025

Verband Deutscher Biologen e.V.

(Bild: DOI: 10.1021/jacs.5c08354 / Hips / CC BY 4.0) Wissenschaftler am Hips entwickelten eine Plattform zur Produktion von Furanoliden, die effektiv gegen Bakterien und Krebszellen wirken können und vielversprechende Wirkstoffe darstellen.

21.10.2025

PROCESS

at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), in partnership with the Helmholtz Centre for Infection Research (HZI

20.10.2025

Bioengineer.org

Register now for the HZI-Newsletter

and stay up to date!

Email address *

We use rapidmail to send our newsletter. I agree that my data entered here will be transmitted to rapidmail. I have taken note of the HZI's privacy policy and have been informed of my rights.